FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
暂无分享,去创建一个
Markus Schwaiger | Andreas Buck | Axel Walch | Zhoulei Li | Ken Herrmann | Michaela Aichler | Nicolas Graf | Ulrich Keller | A. Feuchtinger | A. Walch | M. Aichler | M. Schwaiger | A. Buck | K. Herrmann | C. Peschel | U. Keller | T. Dechow | Christian Peschel | Annette Feuchtinger | Alexandra Jünger | Anja Baumgart | Tobias Dechow | Zhoulei Li | A. Baumgart | Nicolas Graf | A. Jünger | N. Graf
[1] D. Levy,et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.
[2] A. Zelenetz,et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Långstrom,et al. Modeling Spheroid Growth, PET Tracer Uptake, and Treatment Effects of the Hsp90 Inhibitor NVP-AUY922 , 2008, Journal of Nuclear Medicine.
[4] M. Sehested,et al. Early Detection of Response to Experimental Chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice , 2010, PloS one.
[5] H. Lane,et al. mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor , 2009, Clinical Cancer Research.
[6] P. Atadja,et al. Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma , 2010, European journal of haematology.
[7] T. Habermann,et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.
[8] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] T. Mattfeldt,et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[10] L. Mortelmans,et al. 18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model , 2009, Journal of Nuclear Medicine.
[11] Andreas K. Buck,et al. Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment , 2008, Molecular Imaging and Biology.
[12] J. Sweetenham. Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma , 2011, Current opinion in hematology.
[13] B. Coiffier,et al. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. , 2009, Blood reviews.
[14] R. Wahl,et al. Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy , 2009 .
[15] S. Larson,et al. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] Suzanne F. Jones,et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Emmanuel Itti,et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.
[18] C. Thompson,et al. Akt-dependent transformation: there is more to growth than just surviving , 2005, Oncogene.
[19] S. Ferrero,et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.
[20] H. Satoh,et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. , 1994, Oncogene.
[21] Ling Tian,et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. , 2006, Cancer research.
[22] J. Tabernero,et al. Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs , 2010, Oncotarget.
[23] A. Zelenetz,et al. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[24] H. Lane,et al. Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET. , 2010, Translational oncology.
[25] T Ido,et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] T. Mattfeldt,et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] Falko Fend,et al. Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma , 2007, Clinical Cancer Research.
[28] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[29] M. O'Doherty,et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] H. Dittmann,et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[32] B. Falini,et al. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. , 2002, Cancer research.
[33] T. Mattfeldt,et al. Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.
[34] S. Morris,et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. , 2000, Blood.
[35] J. R. Grierson,et al. Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) , 2000 .
[36] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[37] A. Buck,et al. Fluoro-3-Deoxythymidine ( [ 18 F ]-FLT ) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease , 2003 .
[38] O. O’Connor,et al. New therapeutic targets and drugs in non-Hodgkin's lymphoma , 2011, Current opinion in hematology.
[39] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[40] I. Lossos,et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] C. Kuntner,et al. Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake , 2011, Clinical Cancer Research.
[42] B. Coiffier,et al. Targeted treatment and new agents in diffuse large B cell lymphoma , 2010, International journal of hematology.
[43] Bruce D Cheson,et al. Role of functional imaging in the management of lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] A. Younes. Beyond chemotherapy: new agents for targeted treatment of lymphoma , 2011, Nature Reviews Clinical Oncology.
[45] D. Levy,et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.
[46] R L Wahl,et al. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.
[47] M. Wasik,et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. , 2001, Cancer research.
[48] Sven N Reske,et al. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.
[49] S. Shousha,et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.